Oral presentation will showcase distinct preclinical profile for potent, selective MALT1 scaffolding inhibitor that is highly differentiated from MALT1 protease inhibitors BOSTON, Nov. 2, 2023...

– Results support axatilimab's promising safety and efficacy profile, and reinforce its potential as a first-in-class CSF-1R monoclonal antibody in chronic graft-versus-host disease – –...

Program participants have exclusive access to the RO element before commercial launch and receive special pricing incentives. BOSTON, Nov. 2, 2023 /PRNewswire/ -- ZwitterCo, the advanced membrane...

CSO Mike Train, CTO Peter Zornio and Power & Water President Bob Yeager will speak at Reuters Energy Transition North America 2023 Conference HOUSTON, Nov. 2, 2023 /PRNewswire/ -- Top executives...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th...